Skip to main content
Advertising

Originally published August 19, 2014 at 4:55 PM | Page modified August 20, 2014 at 6:28 AM

  • Share:
             
  • Comments
  • Print

Oncothyreon stock sinks on disappointing clinical study results


Seattle Times business staff

advertising

The stock of Seattle biotechnology company Oncothyreon sank 48 cents, or 17.3 percent, to $2.30 Tuesday after it said that its experiment cancer therapy, tecemotide, failed in a clinical study in Japan to improve overall survival in patients with non-small cell lung cancer.

Wedbush analysts expect Oncothyreon partner Merck to discontinue the tecemotide program because of the lack of clinical benefit. Tecemotide was designed to work by stimulating the body’s immune system so that it could identify and destroy cancer cells.



Free 4-week trial, then $99 a year for unlimited seattletimes.com access. Try it now!

Also in Business & Technology

News where, when and how you want it

Email Icon

Enter to win!

Enter to win!

Share a photo of your holiday lights display and you may win a $100 Home Depot gift card.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►